As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
GLP-1 receptor agonists are driving growing demand for nonsurgical treatments to address 'Ozempic face'. HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight ...
al. emphasized the importance of shared decision-making in managing pulmonary aspiration risks for patients on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) ...
It's possible that Alzheimer's disease could be added to the lengthening list of health conditions that can be improved by treatment with GLP-1 receptor agonists. The phase 2 ELAD study of Novo ...
To assess the impact of GLP-1 agonists on incidence and management of adhesive capsulitis, Bergstein and colleagues used the PearlDiver database to perform a retrospective cohort comparison of ...
(Prior studies have simply found a link between taking a GLP-1 receptor agonist and drinking less—but didn’t go so far as to actually prove that the medications caused people to drink less.) ...
A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...
FRIDAY, Jan. 14, 2025 (HealthDay News) -- Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation ...
A recent study found that over a third of websites selling compounded diabetes and weight loss medications, such as Ozempic ...
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...